alzheon, Author at Alzheon | Preserving Future Memories - Page 2 of 21

About alzheon

This author has not yet filled in any details.
So far alzheon has created 208 blog entries.

25 Jun, 2024

Two Peer-Reviewed Scientific Publications Describe Fluid Biomarker, Brain Preservation and Clinical Benefits Following 2 Years of Treatment in Phase 2 Trial Evaluating Oral ALZ-801/Valiltramiprosate in APOE4 Carriers with Early Alzheimer’s Disease

alzheon2024-08-26T11:05:55-04:00June 25th, 2024|

24 Jun, 2024

Alzheon nabs $100M in series E to advance oral Alzheimer’s drug

alzheon2024-06-26T15:07:42-04:00June 24th, 2024|Tags: BioWorld|

20 Jun, 2024

Analysis of Cerebrospinal Fluid, Plasma β-Amyloid Biomarkers, and Cognition from a 2-Year Phase 2 Trial Evaluating Oral ALZ-801/Valiltramiprosate in APOE4 Carriers with Early Alzheimer’s Disease Using Quantitative Systems Pharmacology Model

alzheon2024-06-20T17:34:11-04:00June 20th, 2024|

20 Jun, 2024

Effects of Oral ALZ-801/Valiltramiprosate on Plasma Biomarkers, Brain Hippocampal Volume, and Cognition: Results of 2-Year Single-Arm, Open-Label, Phase 2 Trial in APOE4 Carriers with Early Alzheimer’s Disease

alzheon2024-06-20T17:34:20-04:00June 20th, 2024|

12 Jun, 2024

Alzheimer’s Drug Developer Alzheon Closes $100M Series E Financing

alzheon2024-06-14T12:13:01-04:00June 12th, 2024|Tags: GEN|

12 Jun, 2024

With fresh $100M, Alzheon lays out strategy for Alzheimer’s approval next year

alzheon2024-06-14T12:25:50-04:00June 12th, 2024|Tags: Firstword Pharma|

12 Jun, 2024

Alzheon Raises $100 Million Series E Financing Round to Advance Development and Commercialization of Oral Tablet ALZ-801/Valiltramiprosate for Treatment of Alzheimer’s Disease

alzheon2024-08-26T10:49:53-04:00June 12th, 2024|

12 Jun, 2024

Alzheon Announces Appointment of Renowned Biopharma Executive Gino Santini to Board of Directors

alzheon2024-08-26T10:54:16-04:00June 12th, 2024|

11 Jun, 2024

Breakthroughs in Alzheimer Research Pave Way for New Era of Treatment: Martin Tolar, MD, PhD

alzheon2024-06-26T14:05:46-04:00June 11th, 2024|

30 Apr, 2024

Alzheon Announces First Patient Dosed in Long-Term Extension of APOLLOE4 Phase 3 Trial of Oral ALZ-801/Valiltramiprosate and Launches 52-Week Extension of Phase 2 Biomarker Trial in Patients with Early Alzheimer’s Disease

alzheon2024-08-26T10:57:45-04:00April 30th, 2024|